Wellington Management Group
VERV

Wellington Management Group’s Verve Therapeutics VERV Stock Holding History

Wellington Management Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-298,688
Closed -$3.35M – 2124
2025
Q2 		$3.35M Buy
298,688
+54,505
+22% +$311K ﹤0.01% 1463
2025
Q1 		$1.12M Sell
244,183
-117,315
-32% -$786K ﹤0.01% 1685
2024
Q4 		$2.04M Buy
361,498
+14,469
+4% +$81.6K ﹤0.01% 1558
2024
Q3 		$1.68M Sell
347,029
-24,271
-7% -$141K ﹤0.01% 1587
2024
Q2 		$1.81M Buy
371,300
+118,266
+47% +$743K ﹤0.01% 1544
2024
Q1 		$3.36M Buy
253,034
+95,793
+61% +$1.27M ﹤0.01% 1424
2023
Q4 		$2.19M Sell
157,241
-635,285
-80% -$7.87M ﹤0.01% 1472
2023
Q3 		$10.5M Sell
792,526
-183,602
-19% -$2.96M ﹤0.01% 1096
2023
Q2 		$18.3M Buy
976,128
+42,961
+5% +$716K ﹤0.01% 961
2023
Q1 		$13.5M Buy
933,167
+74,065
+9% +$1.45M ﹤0.01% 1027
2022
Q4 		$16.6M Sell
859,102
-151,606
-15% -$4.02M ﹤0.01% 960
2022
Q3 		$34.7M Sell
1,010,708
-252,676
-20% -$8.06M 0.01% 752
2022
Q2 		$19.3M Sell
1,263,384
-1,082,663
-46% -$16.8M ﹤0.01% 954
2022
Q1 		$53.5M Sell
2,346,047
-1,593,461
-40% -$45.5M 0.01% 734
2021
Q4 		$145M Sell
3,939,508
-654,718
-14% -$27.5M 0.02% 529
2021
Q3 		$214M Buy
4,594,226
+628,747
+16% +$37M 0.04% 423
2021
Q2 		$232M Buy
+3,965,479
New +$165M 0.04% 406

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wellington Management Group's VERV Position: Q3 2025 in Review

Wellington Management Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 298,688 shares — an estimated $3.35M sold.

Wellington Management Group first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $232M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Wellington Management Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wellington Management Group sold 298,688 Verve Therapeutics shares in Q3 2025, an estimated $3.35M.
  • Wellington Management Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Wellington Management Group's Verve Therapeutics position peaked at $232M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Wellington Management Group's 13F filing for Q3 2025, filed 14 Nov 2025.